articleJournal of the American Pharmacists AssociationOct 10, 2023HYBRID OA

Trends in glucagon-like peptide 1 receptor agonist use, 2014 to 2022

JHJonathan H. WatanabeJKJimmy KwonBNBin NanARAndrew Reikes
PubMed
Indexed incrossrefpubmed

Abstract

Background

Recent Food and Drug Administration approvals of glucagon-like peptide 1 (GLP-1) receptor agonists linked to substantial weight loss have generated interest in demand projections. However, a longitudinal analysis in a large, diverse, current, real-world database has not been published.

Objectives

The study objective was to determine user frequency of GLP-1 receptor agonist products overall and by type 2 diabetes (T2D), cardiovascular disease (CVD), and overweight or obese status. Secondary objective was monthly growth rate estimation by product since first appearance in University of California Health.

Citation impact

178
total citations
FWCI
32.04
Percentile
100%
References
26
Citations per year

Authors

4

Topics & keywords

Topics
Keywords
  • Medicine
  • Agonist
  • Glucagon-like peptide-1
  • Glucagon-like peptide 1 receptor
  • Pharmacology
  • Receptor
  • Internal medicine
  • Endocrinology
No related works found for this paper.

Funding